U.S. Clinical Trial Imaging Market Size, Share & Growth Report, 2033
The U.S. clinical trial imaging market size was valued at USD 409.50 million in 2023 and is projected to surpass around USD 875.93 million by 2033, registering a CAGR of 7.9% over the forecast period of 2024 to 2033.
The U.S. clinical trial imaging market is characterized by a comprehensive landscape that encompasses various aspects. This market involves the utilization of imaging technologies such as MRI, CT scans, and PET scans to facilitate clinical trials. These imaging modalities play a crucial role in enhancing the accuracy and depth of assessments regarding patient responses to treatments. Moreover, the market is driven by the increasing prevalence of chronic diseases, which necessitates the development of novel therapeutics and subsequently leads to a higher demand for clinical trials. Regulatory agencies also contribute significantly to market dynamics by emphasizing the incorporation of imaging endpoints in clinical trials to better evaluate treatment efficacy and safety. Furthermore, the integration of artificial intelligence (AI) and machine learning algorithms in imaging analysis has revolutionized processes, making them more efficient and facilitating faster decision-making. Additionally, the trend towards decentralized clinical trials and the adoption of remote imaging technologies have further expanded the reach of clinical trials, driving innovation within the U.S. clinical trial imaging market.
| Report Attribute | Details |
| Market Size in 2024 | USD 441.85 million |
| Market Size by 2033 | USD 875.93 million |
| Growth Rate From 2024 to 2033 | CAGR of 7.9% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Service, modality, application, end-use |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | IXICO plc; Navitas Life Sciences; Resonance Health; ProScan Imaging; Radiant Sage LLC; Medpace; Biomedical Systems Corp; Cardiovascular Imaging Technologies; Intrinsic Imaging; BioTelemetry |
The market's growth is expected to be fueled by rapid growth and increasing investments in the pharmaceutical and biotechnology sectors. Also, the surge in R&D initiatives for new drug development is advantageous for market growth.
The presence of established CROs in the U.S. providing clinical trial services and the increasing number of clinical trials are driving the demand for clinical trial imaging solutions. According to estimates by Clinicaltrial.gov, as of December 2023, there were 145,218 registered studies for clinical trials in the country, accounting for 31% of total clinical trials globally. A high percentage of clinical trials across the U.S. is creating lucrative opportunities for the market players. Furthermore, high R&D spending on clinical trials has supplemented market growth. In October 2021, the FDA approved over 11 new clinical trial research, which resulted in USD 25 million in funding for four years. These grants support the development of advanced medical devices and imaging technologies for treating various diseases.
In 2023, the U.S. accounted for a market share of over 36.0% in the global clinical trial imaging market. The growing concerns about diagnostic safety and efficiency of medical imaging devices have contributed to the demand growth for clinical trial imaging. The increased adoption of medical imaging technology in primary care settings, enhanced accessibility, and high healthcare spending in the country with efficient reimbursement policies are opportunistic for market growth.
Project & data management services were identified as the largest segment, with a 28.17% share in 2023. Clinical trial imaging typically requires robust data management and unified coordination among numerous stakeholders. These services comprise key aspects, such as developing trial workflows, operational expertise, project tracking, transforming scans into digital images, quality assurance, real-time reporting, establishing MRI centres, data management, regulatory approvals, and resolution. Furthermore, the U.S. government has approved a cloud-driven server to secure all medical imaging records while ensuring protection against natural disasters. This system enables faster and more convenient retrieval of critical medical records.
System and technology support services are projected to grow significantly over the forecast period. This segment covers support services throughout various imaging modalities, such as MRI, ultrasound, CT, PET, OCT, and SPECT, which find applications in oncology, neurology, gastroenterology, cardiovascular diseases, musculoskeletal disorders, and medical device research for conducting clinical trials. The technological advancements in devices are anticipated to fuel the segment's growth.
Computed Tomography (CT) scans captured the highest market share of 29.19% in 2023. CT scans deliver more detailed images of the body's internal structures than conventional radiography. Patients are generally more comfortable with CT than MRI because the machine is less noisy and faster. A CT scan generally lasts 5 to 10 minutes compared to 30 minutes in the case of an MRI. As factors such as patient movement and breath-holding do not affect the quality of the image produced, CT is the preferred imaging modality, especially among the paediatric & geriatric population.
The ultrasound segment is expected to grow at the fastest CAGR during the forecast period. The growing use of ultrasound technology in cardiovascular and abdominal diseases is expected to boost market demand in the country. Furthermore, increasing public and private investments in developing advanced ultrasound technologies, training programs, and teleradiology services are likely to aid market growth.
Oncology clinical trial imaging held the largest market share of 26.17% in 2023. The number of people diagnosed with cancer is expected to increase multi-fold in the upcoming decade. Factors including the growing prevalence of cancer cases and the increasing need for advanced therapies for treating different types of cancer are projected to fuel the segment's growth. Oncology clinical trials involve complicated imaging requirements owing to the need to analyse tumour’s and disease progression. Different imaging modalities, including MRI, CT scans, PET scans, and others, are deployed to evaluate the efficacy of cancer treatments.
The Non-alcoholic Steatohepatitis (NASH) segment is anticipated to grow fastest during the forecast period. The prevalence of NASH is expected to increase to over 66% by 2033, fuelling the need for its treatment. Companies in this market are enhancing clinical trial studies to evaluate the efficiency of therapies adopted for NASH. This is projected to be opportunistic for the segment growth.
The contract research organizations (CROs) segment accounted for the largest share of 45.19% in 2023. Many pharmaceutical and biotechnology companies are increasingly outsourcing clinical trials to specialized contract research organizations (CROs) to leverage their expertise, reduce costs, and accelerate the drug development process. CROs cater to a wide range of full-time and functional services to support different development stages.
The academic and government research institutes segment is expected to grow significantly over the forecast period. The increasing focus on developing novel therapeutics, the growing prevalence of rare diseases, and the rising number of clinical trials in terms of experimental & observational studies are some factors supporting segment growth. Moreover, the surging number of research institutes and the growing focus on discovering novel ways to conduct clinical trials & avoid the usage of animal models are some factors augmenting segment growth.
The key U.S. clinical trial imaging companies include ProScan Imaging, IXICO plc, and Biomedical Systems Corp. Numerous market players are expanding their global footprint by establishing collaborations, partnerships, and acquisitions to tap into new markets and countries. Collaborations with healthcare providers and research institutions, such as the Mayo Clinic and academic medical centers, are opportunistic to access expertise and assess their technologies in real-world clinical settings.
U.S. Clinical Trial Imaging Market Top Key Companies:
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Clinical Trial Imaging market.
By Service
By Modality
By Application
By End-use
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers